Jump to content

Antibody-oligonucleotide conjugate

Edit links
From Wikipedia, the free encyclopedia

This is an old revision of this page, as edited by Bioconjugator (talk | contribs) at 13:18, 26 August 2019. The present address (URL) is a permanent link to this revision, which may differ significantly from the current revision.

Schematic structure of an antibody-oligonucleotide conjugate (AOC)

Antibody-oligonucleotide conjugates or AOCs belong to a class of chimeric molecules combining in their structure two important families of biomolecules: monoclonal antibodies and oligonucleotides.

History

Combination of exceptional targeting capabilities of monoclonal antibodies with numerous functional modalities of oligonucleotides has been fruitful for a variety of applications with AOC including imaging, detection and targeted therapeutics.[1][2][3]

References

  1. ^ Dovgan, Igor; Koniev, Oleksandr; Kolodych, Sergii; Wagner, Alain (24 July 2019). "Antibody–Oligonucleotide Conjugates as Therapeutic, Imaging, and Detection Agents". Bioconjugate Chemistry. doi:10.1021/acs.bioconjchem.9b00306. ISSN 1043-1802. Retrieved 26 August 2019.
  2. ^ Levin, Arthur A. (2017-01-05). Phimister, Elizabeth G. (ed.). "Targeting Therapeutic Oligonucleotides". New England Journal of Medicine. 376 (1). Massachusetts Medical Society: 86–88. doi:10.1056/nejmcibr1613559. ISSN 0028-4793.
  3. ^ Winkler, Johannes (2013). "Oligonucleotide conjugates for therapeutic applications". Therapeutic Delivery. 4 (7). Future Science Ltd: 791–809. doi:10.4155/tde.13.47. ISSN 2041-5990.
Retrieved from "https://en.wikipedia.org/enwiki/w/index.php?title=Antibody-oligonucleotide_conjugate&oldid=912563453"